Advances in the prevention, management, and treatment of community-acquired pneumonia

Community-acquired pneumonia (CAP) is the infectious disease with the highest number of deaths worldwide. Nevertheless, its importance is often underestimated. Large cohorts of patients with CAP have been established worldwide and improved our knowledge about CAP by far. Therefore, current guidelines are much more evidence-based than ever before. This article discusses recent major studies and concepts on CAP such as the role of biomarkers, appropriate risk stratification to identify patients in need of hospitalisation or intensive care, appropriate empiric antibiotic therapy (including the impact of macrolide combination therapy and antibiotic stewardship), and CAP prevention with novel influenza and pneumococcal vaccines.

[1]  T. Welte,et al.  The Burden of Pneumococcal Pneumonia – Experience of the German Competence Network CAPNETZ , 2012, Pneumologie.

[2]  I. Pavord,et al.  Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function , 2015, International journal of chronic obstructive pulmonary disease.

[3]  Sebastian Schneeweiss,et al.  Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. , 2006, Journal of clinical epidemiology.

[4]  T. Welte,et al.  Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. , 2009, The Journal of antimicrobial chemotherapy.

[5]  A. Akram,et al.  Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients , 2011, European Respiratory Journal.

[6]  W. Lim,et al.  Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.

[7]  J. Holden,et al.  Vaccines for preventing pneumococcal infection in adults. , 2008, The Cochrane database of systematic reviews.

[8]  H. Svanström,et al.  Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study , 2014, BMJ : British Medical Journal.

[9]  D M Fleming,et al.  An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998–1999 to 2005–2006 , 2010, Epidemiology and Infection.

[10]  T. Perneger,et al.  β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. , 2014, JAMA internal medicine.

[11]  G. Rücker,et al.  Performance of a novel microarray multiplex PCR for the detection of 23 respiratory pathogens (SYMP-ARI study) , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[12]  J. Ramirez,et al.  Effects of Fluoroquinolones on the Migration of Human Phagocytes through Chlamydia pneumoniae-Infected and Tumor Necrosis Factor Alpha-Stimulated Endothelial Cells , 2004, Antimicrobial Agents and Chemotherapy.

[13]  T. Marrie,et al.  Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: a population-based cohort study. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  T. Welte,et al.  Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis , 2011, European Respiratory Journal.

[15]  Robert George,et al.  Bacterial Pneumonia and Pandemic Influenza Planning , 2008, Emerging infectious diseases.

[16]  B. Rubin,et al.  Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. , 2008, Pharmacology & therapeutics.

[17]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[18]  J. Hippisley-Cox,et al.  Risk of pneumonia in patients taking statins: population-based nested case-control study. , 2011, The British journal of general practice : the journal of the Royal College of General Practitioners.

[19]  M. Fine,et al.  Cardiac Complications in Patients With Community-Acquired Pneumonia: Incidence, Timing, Risk Factors, and Association With Short-Term Mortality , 2012, Circulation.

[20]  A. Torres,et al.  Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality , 2011, European Respiratory Journal.

[21]  A. Akram,et al.  Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies , 2013, BMJ.

[22]  John Earl,et al.  Efficacy of high-dose versus standard-dose influenza vaccine in older adults. , 2014, The New England journal of medicine.

[23]  S. Quintana,et al.  Effects of systemic steroids in patients with severe community-acquired pneumonia , 2007, European Respiratory Journal.

[24]  Oliver Hartmann,et al.  Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. , 2010, American journal of respiratory and critical care medicine.

[25]  F. Gudiol,et al.  Statins for community-acquired pneumonia: current state of the science , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[26]  A. Ma,et al.  Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. , 2007, Chest.

[27]  B. Rubin,et al.  Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[28]  T. Welte,et al.  Community-acquired pneumonia as medical emergency: predictors of early deterioration , 2015, Thorax.

[29]  S. Suissa,et al.  Differences between asthmatics and nonasthmatics hospitalised with influenza A infection , 2013, European Respiratory Journal.

[30]  Y. Loke,et al.  Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis , 2010, Thorax.

[31]  O. Ramilo,et al.  Antimicrobial and Immunologic Activities of Clarithromycin in a Murine Model of Mycoplasma pneumoniae-Induced Pneumonia , 2003, Antimicrobial Agents and Chemotherapy.

[32]  Cliodna McNulty,et al.  Narrative review of primary care point-of-care testing (POCT) and antibacterial use in respiratory tract infection (RTI) , 2015, BMJ Open Respiratory Research.

[33]  Faran Bokhari,et al.  Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine , 2008, Critical care medicine.

[34]  J. Nelson,et al.  Statin use and risk of community acquired pneumonia in older people: population based case-control study , 2009, BMJ : British Medical Journal.

[35]  A. Anzueto,et al.  Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. , 2015, JAMA.

[36]  J. Hedlund,et al.  Improvement of CRB-65 as a prognostic tool in adult patients with community-acquired pneumonia , 2014, BMJ Open Respiratory Research.

[37]  D. Grobbee,et al.  Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. , 2015, The New England journal of medicine.

[38]  W. Lim,et al.  Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. , 2015, The Journal of infectious diseases.

[39]  F. Blasi,et al.  Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. , 2005, American journal of respiratory and critical care medicine.

[40]  T. Welte,et al.  Pneumococcal and influenza vaccination , 2014 .

[41]  T. Welte,et al.  Clinical and economic burden of community-acquired pneumonia among adults in Europe , 2010, Thorax.

[42]  T. Welte,et al.  New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality , 2009, Thorax.

[43]  S. Richter,et al.  Changes in Pneumococcal Serotypes and Antimicrobial Resistance after Introduction of the 13-Valent Conjugate Vaccine in the United States , 2014, Antimicrobial Agents and Chemotherapy.

[44]  G. Rohde,et al.  Pneumococcal infection in adults: burden of disease. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[45]  T. Lim,et al.  The impact of a delay in intensive care unit admission for community-acquired pneumonia , 2010, European Respiratory Journal.

[46]  T. Welte,et al.  Global and Local Epidemiology of Community-Acquired Pneumonia: The Experience of the CAPNETZ Network , 2009, Seminars in respiratory and critical care medicine.

[47]  T. Welte,et al.  Dysnatremia, vasopressin, atrial natriuretic peptide and mortality in patients with community-acquired pneumonia: results from the german competence network CAPNETZ. , 2014, Respiratory medicine.

[48]  Mathias W Pletz,et al.  Chronic Obstructive Pulmonary Diseases : Journal of the COPD Foundation Increased Severity and Mortality of CAP in COPD : Results from the German Competence Network , CAPNETZ , 2015 .

[49]  Mathias W Pletz,et al.  Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study , 2011, BMC Infectious Diseases.

[50]  C. Schumann,et al.  Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study , 2012, BMJ : British Medical Journal.

[51]  M. Leinonen,et al.  Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice. , 2004, The Journal of antimicrobial chemotherapy.

[52]  R. Schlienger,et al.  Statins and the Risk of Pneumonia: A Population‐Based, Nested Case‐Control Study , 2007, Pharmacotherapy.

[53]  J. Maurer.  Validation of the Infectious Diseases Society of America/American Thoratic Society Minor Criteria for Intensive Care Unit Admission in Community-Acquired Pneumonia Patients Without Major Criteria or Contraindications to Intensive Care Unit Care , 2012 .

[54]  T. Welte,et al.  Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  A. Ruiz-González,et al.  Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. , 1999, The American journal of medicine.

[56]  R. Wunderink,et al.  Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia , 2009, European Respiratory Journal.

[57]  Rui Wang,et al.  The cardiotoxicity of macrolides: a systematic review. , 2010, Die Pharmazie.

[58]  H. Blau,et al.  Anti-Inflammatory Effects of Moxifloxacin on Activated Human Monocytic Cells: Inhibition of NF-κB and Mitogen-Activated Protein Kinase Activation and of Synthesis of Proinflammatory Cytokines , 2004, Antimicrobial Agents and Chemotherapy.

[59]  D. Trapani,et al.  Antibiotic treatment strategies for community-acquired pneumonia in adults , 2015, Internal and Emergency Medicine.

[60]  R. Veenhoven,et al.  Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. , 2009, Vaccine.

[61]  W. Bos,et al.  Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.

[62]  N. Suttorp,et al.  Assessment of oxygenation and comorbidities improves outcome prediction in patients with community‐acquired pneumonia with a low CRB‐65 score , 2015, Journal of internal medicine.

[63]  A. Akram,et al.  Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  M. Niederman,et al.  Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial , 2010, BMJ : British Medical Journal.

[65]  W. Boersma,et al.  Efficacy of Corticosteroids in Community-acquired Pneumonia a Randomized Double-blinded Clinical Trial at a Glance Commentary , 2022 .

[66]  O. Ramilo,et al.  Impact of Cethromycin (ABT-773) Therapy on Microbiological, Histologic, Immunologic, and Respiratory Indices in a Murine Model of Mycoplasma pneumoniae Lower Respiratory Infection , 2004, Antimicrobial Agents and Chemotherapy.

[67]  G. Rücker,et al.  Detection of respiratory viruses using a multiplex real-time PCR assay in Germany, 2009/10 , 2013, Archives of Virology.

[68]  P. Nikolaides,et al.  Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment , 2002, Antimicrobial Agents and Chemotherapy.

[69]  M. Fine,et al.  Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? , 2006, Chest.

[70]  D. Grobbee,et al.  Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. , 2008, The Netherlands journal of medicine.

[71]  C Michael Stein,et al.  Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.

[72]  T. Schaberg,et al.  Guidelines for the management of adult lower respiratory tract infections ‐ Full version , 2011, Clinical Microbiology and Infection.

[73]  Á. Soriano,et al.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  M. Woodhead.  Faculty Opinions recommendation of Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. , 2013 .

[75]  R. Hubbard,et al.  Risk of community‐acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population‐based case–control study , 2009, Pharmacoepidemiology and drug safety.

[76]  J. Hedlund,et al.  Improvement of CRB-65 as a prognostic scoring system in adult patients with bacteraemic pneumococcal pneumonia , 2011, Scandinavian journal of infectious diseases.

[77]  B. Bošnjak,et al.  Azithromycin and Clarithromycin Inhibit Lipopolysaccharide-Induced Murine Pulmonary Neutrophilia Mainly through Effects on Macrophage-Derived Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-1β , 2009, Journal of Pharmacology and Experimental Therapeutics.

[78]  A. El‐Solh,et al.  Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia. , 2010, Chest.

[79]  H. Raspe,et al.  Approaches to estimate the population-based incidence of community acquired pneumonia. , 2007, The Journal of infection.

[80]  J. Dorca,et al.  Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes , 2009, Thorax.

[81]  T. Welte,et al.  Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection , 2010, European Respiratory Journal.

[82]  K. Riesbeck.  Immunomodulating Activity of Quinolones: Review , 2002, Journal of chemotherapy.

[83]  J. Chalmers,et al.  A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. , 2014, The Journal of antimicrobial chemotherapy.

[84]  A. Torres,et al.  Guidelines for the management of adult lower respiratory tract infections , 2005, European Respiratory Journal.

[85]  A. Gonzalez,et al.  Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. , 2007, American journal of respiratory and critical care medicine.

[86]  F. Tubach,et al.  Procalcitonin to Guide Initiation and Duration of Antibiotic Treatment in Acute Respiratory Infections: An Individual Patient Data Meta-Analysis , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  J. Ramirez,et al.  Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. , 2008, Chest.

[88]  T. Welte,et al.  Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes , 2008, European Respiratory Journal.

[89]  Bing Li,et al.  β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.

[90]  N. Rodondi,et al.  Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial , 2015, The Lancet.

[91]  T. Marrie,et al.  Admission hypoglycemia and increased mortality in patients hospitalized with pneumonia. , 2010, The American journal of medicine.

[92]  T. Lim,et al.  IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia , 2013, European Respiratory Journal.

[93]  T. Welte,et al.  CRB‐65 predicts death from community‐acquired pneumonia * , 2006, Journal of internal medicine.

[94]  J. Dorca,et al.  Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial , 2011, Critical care.

[95]  T. Welte,et al.  Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP – Results from the German competence network CAPNETZ , 2009, Respiratory Research.

[96]  M. Bonten,et al.  Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. , 2005, The Netherlands journal of medicine.

[97]  C. Vogelmeier,et al.  Suppression of pulmonary innate host defence in smokers , 2008, Thorax.

[98]  N. Wellinghausen,et al.  Low prevalence of Chlamydia pneumoniae in adults with community-acquired pneumonia. , 2006, International journal of medical microbiology : IJMM.

[99]  W. Schaffner,et al.  Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. , 2008, The Journal of infectious diseases.

[100]  A. Akram,et al.  Statins in community acquired pneumonia: Evidence from experimental and clinical studies. , 2010, Respiratory medicine.

[101]  P. Sullivan,et al.  Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003. , 2008, Vaccine.

[102]  N. Krug,et al.  Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. , 2008, International journal of antimicrobial agents.

[103]  M. Fine,et al.  Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. , 2014, JAMA.

[104]  M. Christ-Crain,et al.  Prognostic value of procalcitonin in community-acquired pneumonia , 2010, European Respiratory Journal.

[105]  S. Kudoh,et al.  Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. , 1998, American journal of respiratory and critical care medicine.

[106]  T. Welte,et al.  Failure of Ambulatory Treatment in CAP Patients Leading to Subsequent Hospitalization and its Association to Risk Factors - Prospective Cohort Study , 2013 .

[107]  T. Welte,et al.  How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired Pneumonia , 2010, European Respiratory Journal.

[108]  T. Welte,et al.  Why Do Nonsurvivors from Community-Acquired Pneumonia Not Receive Ventilatory Support? , 2013, Lung.

[109]  Anthony S Fauci,et al.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. , 2008, The Journal of infectious diseases.

[110]  T. Welte,et al.  Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups , 2012, European Respiratory Journal.

[111]  K. Krogfelt,et al.  Temporal Trends in Invasive Pneumococcal Disease and Pneumococcal Serotypes over 7 Decades , 2010, Journal of British Studies.

[112]  T. Welte,et al.  Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ) , 2009, BMC infectious diseases.

[113]  J. Hedlund,et al.  Etiology of Community-Acquired Pneumonia: Increased Microbiological Yield with New Diagnostic Methods , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[114]  J. Dorca,et al.  The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial , 2015, BMJ Open.

[115]  C. Whitney,et al.  Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[116]  P. Crosbie,et al.  Long-term macrolide therapy in chronic inflammatory airway diseases , 2009, European Respiratory Journal.

[117]  H. Sitter,et al.  Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community-acquired Pneumonia , 2010, Pneumologie.

[118]  M. P. van der Linden,et al.  Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany , 2015, PloS one.

[119]  J. Ramirez,et al.  Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia , 2015, ERJ Open Research.

[120]  S. Kudoh,et al.  Erythromycin treatment in diffuse panbronchiolitis. , 1998, Current opinion in pulmonary medicine.

[121]  S. Ewig,et al.  Management-based risk prediction in community-acquired pneumonia by scores and biomarkers , 2012, European Respiratory Journal.

[122]  A. Akram,et al.  Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis , 2011, Intensive Care Medicine.

[123]  S. Ōmura,et al.  Molecular Mechanisms of Anti-Inflammatory Action of Erythromycin in Human Bronchial Epithelial Cells: Possible Role in the Signaling Pathway That Regulates Nuclear Factor-κB Activation , 2004, Antimicrobial Agents and Chemotherapy.

[124]  José A. Martínez,et al.  Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[125]  T. Welte,et al.  Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[126]  A. Akram,et al.  Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis , 2010, Thorax.

[127]  S. Gorman,et al.  Corticosteroid Treatment of Severe Community-Acquired Pneumonia , 2007, The Annals of pharmacotherapy.

[128]  Le-Xin Wang,et al.  Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. , 2016, Chest.

[129]  Pascal Crépey,et al.  Retrospective public health impact of a quadrivalent influenza vaccine in the United States , 2015, Influenza and other respiratory viruses.

[130]  J. Ramirez,et al.  Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis , 2014, Respiratory Research.

[131]  J. Chalmers,et al.  Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data , 2013, European Respiratory Journal.

[132]  A. Lindstrand,et al.  Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden , 2016, European Respiratory Journal.